uniQure N.V. Amortization of Debt Discount (Premium)
uniQure N.V. (QURE) reported Amortization of Debt Discount (Premium) of -$4.33 million for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:AmortizationOfDebtDiscountPremium · last filed 2026-05-05
- uniQure N.V. amortization of debt discount (premium) for the quarter ending 2026-03-31 was -$4.33M.
- uniQure N.V. amortization of debt discount (premium) for the quarter ending 2025-12-31 was -$4.37M.
- uniQure N.V. amortization of debt discount (premium) for the quarter ending 2025-09-30 was -$1.93M.
- uniQure N.V. amortization of debt discount (premium) for the quarter ending 2025-06-30 was -$2.05M.
- uniQure N.V. amortization of debt discount (premium) for fiscal 2025 was -$10.46M.
- uniQure N.V. amortization of debt discount (premium) for fiscal 2024 was -$10.90M.
- uniQure N.V. amortization of debt discount (premium) for fiscal 2023 was -$10.92M.
| Period end | Amortization of Debt Discount (Premium) 3 month | Amortization of Debt Discount (Premium) 6 month | Amortization of Debt Discount (Premium) 9 month | Amortization of Debt Discount (Premium) 12 month |
|---|---|---|---|---|
| 2026-03-31 | -$4.33M 10-Q · filed 2026-05-05 | -$8.71M derived: sum of 2 quarters · filed 2026-05-05 | -$10.63M derived: sum of 3 quarters · filed 2026-05-05 | -$12.68M derived: sum of 4 quarters · filed 2026-05-05 |
| 2025-12-31 | -$4.37M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | -$6.30M derived: sum of 2 quarters · filed 2026-03-02 | -$8.35M derived: sum of 3 quarters · filed 2026-03-02 | -$10.46M 10-K · filed 2026-03-02 |
| 2025-09-30 | -$1.93M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | -$3.97M derived: sum of 2 quarters · filed 2025-11-10 | -$6.09M 10-Q · filed 2025-11-10 | -$8.52M derived: sum of 4 quarters · filed 2026-05-05 |
| 2025-06-30 | -$2.05M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-29 | -$4.16M 10-Q · filed 2025-07-29 | -$6.59M derived: sum of 3 quarters · filed 2026-05-05 | -$8.39M derived: sum of 4 quarters · filed 2026-05-05 |
| 2025-03-31 | -$2.12M 10-Q · filed 2026-05-05 | -$4.55M derived: sum of 2 quarters · filed 2026-05-05 | -$6.35M derived: sum of 3 quarters · filed 2026-05-05 | -$9.32M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | -$2.43M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | -$4.23M derived: sum of 2 quarters · filed 2026-03-02 | -$7.21M derived: sum of 3 quarters · filed 2026-03-02 | -$10.90M 10-K · filed 2026-03-02 |
| 2024-09-30 | -$1.80M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | -$4.78M derived: sum of 2 quarters · filed 2025-11-10 | -$8.47M 10-Q · filed 2025-11-10 | -$12.86M derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-06-30 | -$2.98M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-29 | -$6.67M 10-Q · filed 2025-07-29 | -$11.06M derived: sum of 3 quarters · filed 2026-03-02 | -$15.75M derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-03-31 | -$3.69M 10-Q · filed 2025-05-09 | -$8.08M derived: sum of 2 quarters · filed 2026-03-02 | -$12.78M derived: sum of 3 quarters · filed 2026-03-02 | -$13.69M derived: sum of 4 quarters · filed 2026-03-02 |
| 2023-12-31 | -$4.39M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | -$9.08M derived: sum of 2 quarters · filed 2026-03-02 | -$9.99M derived: sum of 3 quarters · filed 2026-03-02 | -$10.92M 10-K · filed 2026-03-02 |
| 2023-09-30 | -$4.69M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-05 | -$5.60M derived: sum of 2 quarters · filed 2024-11-05 | -$6.53M 10-Q · filed 2024-11-05 | |
| 2023-06-30 | -$912.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | -$1.84M 10-Q · filed 2024-08-01 | ||
| 2023-03-31 | -$925.00K 10-Q · filed 2024-05-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |